Blau Farmac?utica S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 08, 2021
Share
Blau Farmac?utica S.A. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was BRL 319.62 million compared to BRL 302.82 million a year ago. Net income was BRL 94.39 million compared to BRL 75.5 million a year ago. Basic earnings per share from continuing operations was BRL 0.53 compared to BRL 0.51 a year ago. Diluted earnings per share from continuing operations was BRL 0.53 compared to BRL 0.51 a year ago.
For the nine months, sales was BRL 1,016.51 million compared to BRL 843.97 million a year ago. Net income was BRL 280.05 million compared to BRL 180.66 million a year ago. Basic earnings per share from continuing operations was BRL 1.6623 compared to BRL 1.22 a year ago. Diluted earnings per share from continuing operations was BRL 1.6623 compared to BRL 1.22 a year ago.
Blau Farmaceutica SA is a Brazil-based company engaged in the pharmaceuticals sector. The Company focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The Company operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.
BLAU FARMACÊUTICA S.A. 
